Skip to main navigation

Contact Us
Join Us
LinkedIn

Our Company
Our Commitment
Our Innovation
Investors and Media
- Column
- Column

Our Company
Our Commitment
Our Innovation
Investors and Media
- Column
- Column

Public Disclosures

Overview
Stock
News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Overview
Stock
News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Public Disclosures

Nov 07, 2024

Q3 2024 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Nine Months Ended September 30, 2024 329.6 KB

Management Discussion and Analysis of Financial Condition and Results of Operations for the Nine Months Ended September 30, 2024 261.1 KB

Aug 27, 2024

Q2 2024 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Six Months Ended June 30, 2024 298.8 KB

Management Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2024 262.4 KB

May 08, 2024

Q1 2024 Financial Results

Unaudited Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2024 228.2 KB

Management Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2024 207.1 KB

Apr 22, 2024

Supplement to Prospectus Nasdaq Iceland Main Market Listing

Oculis Supplement to Prospectus Nasdaq Iceland Main Market Listing 802.1 KB

Apr 11, 2024

Prospectus Nasdaq Iceland Main Market Listing

Oculis Prospectus Nasdaq Iceland Main Market Listing 2.1 MB

Rethinking Ophthalmology

Our Company
About Us
Our Team
Our Culture
Contact Us
Join Us
LinkedIn

Our Commitment
Diabetic Macular Edema I OCS-01
Post Ocular Surgery I OCS-01
Dry Eye Disease I OCS-02
Uveitis ׀ OCS-02
Acute Optic Neuritis ׀ OCS-05

Our Innovation
Pipeline
Clinical Trials
Science
Publications

Investors and Media
Overview
Stock Information
News Releases
Events & Presentations
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources

© 2024 Oculis All Rights Reserved

Terms of Use
Privacy Notice
Cookie Policy
Expanded Access Policy